Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Rational Structure-Based Design of Broad Neutralizing Humanized svMP mAbs

Award Number: R21AI156156
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/02/2020
PERIOD OF PERFORMANCE END DATE: 11/30/2024

Group Awards By:

View Award Description

Rational Structure-Based Design of Broad Neutralizing Humanized svMP mAbs - PROJECT SUMMARY In this R21 award, we aim to develop a novel and broad neutralizing human monoclonal antibody for treating snakebite envenoming by rational structure-based design in order to produce a more effective and safer next generation antivenom. Snake envenomation is a serious global public health concern and ranked on the Wor ld Health Organization’s list of neglected tropical diseases, killing on average 125,000 people per year and leaving another 400,000 permanently disabled. The majority of snake envenomation in the US, inflicted by members of the snake family Viperidae, causes local tissue damage (such as myonecrosis, blisters, and local inflammation and pain) and systemic effects, including hemorrhage and coagulopathies which can lead to shock, renal failure and death. Snake venom metalloproteinases are major causative agents for spontaneous systemic bleeding and coagulopathies. Current antivenoms, produced by immunization of domestic animals, have limited efficacy in the prevention of both local and systemic effects of Viperidae envenomation as well as an associated risk of hypersensitivity reactions. Our long-term goal is to develop novel, effective humanized antivenom therapeutics for Viperidae envenomation. The objective of this project is to test the hypothesis that camelid-inspired inhibitory paratope synthetic human antibodies targeted to the active site of medically-relevant viperid venom metalloproteinases (svMPs) can provide broad antivenom protection without cross-reaction with human metalloproteinases and without the risk of hypersensitivity. This objective will be addressed through our established collaboration of complementary expertise between the snake venom toxinology team at National Natural Toxins Research Center (NNTRC) and the antibody discovery team at University of California Riverside (UCR). To test our hypothesis, we will address the following three Specific Aims. Aim 1: Qualitative and Quantitative Characterization of the hemorrhagic activity of viperid svMPs (Galan), Aim 2: Discovery of Broadly Neutralizing svMP-Specific Human mAbs (Ge). Aim 3: Evaluation of the antivenom efficacy of svMP inhibitory mAbs in vitro (Ge) and in vivo (Sanchez). The proposed research is significant because it will advance our understanding of the hemorrhagic aspects caused by snake envenomation at biochemical/cellular levels and develop effective humanized mAb antivenoms, which will be directly translatable for therapeutic use. The novelties of our project are (1) development and application of a novel Hemorrhage Score system to characterize svMPs; (2) isolation of humanized svMP-specific antivenom mAbs from libraries carrying novel convex paratopes; (3) development groundbreaking functional (rather than binding-based) HTS for facile discovery of mAbs inhibiting hemorrhagic snake toxins; and (4) potentially shifting the conventional antivenom production into specific neutralizing humanized mAb therapeutics.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$6,326 )
2025	2022	TEXAS A & M UNIVERSITY KINGSVILLE	700 N UNIVERSITY BLVD	KINGSVILLE	TX	78363	KLEBERG	USA	Allergy and Infectious Diseases Research	000	2	4/15/2025	NON-COMPETING CONTINUATION	-$6,326
														Subtotal = -$6,326

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	TEXAS A & M UNIVERSITY KINGSVILLE	700 N UNIVERSITY BLVD	KINGSVILLE	TX	78363	KLEBERG	USA	Allergy and Infectious Diseases Research	000	2	12/1/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $183,948 )
2022	2022	TEXAS A & M UNIVERSITY KINGSVILLE	700 UNIVERSITY BLVD	KINGSVILLE	TX	78363	KLEBERG	USA	Allergy and Infectious Diseases Research	001	2	8/18/2022	NON-COMPETING CONTINUATION	$0
2022	2022	TEXAS A & M UNIVERSITY KINGSVILLE	700 UNIVERSITY BLVD	KINGSVILLE	TX	78363	KLEBERG	USA	Allergy and Infectious Diseases Research	000	2	11/18/2021	NON-COMPETING CONTINUATION	$183,948
														Subtotal = $183,948

Issue Date FY: 2021 ( Subtotal = $216,935 )
2021	2021	TEXAS A & M UNIVERSITY KINGSVILLE	700 UNIVERSITY BLVD	KINGSVILLE	TX	78363	KLEBERG	USA	Allergy and Infectious Diseases Research	000	1	12/1/2020	NEW	$216,935
														Subtotal = $216,935

Grand Total All Awards = $394,557

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Rational Structure-Based Design of Broad Neutralizing Humanized svMP mAbs

Award Number: R21AI156156

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/02/2020

PERIOD OF PERFORMANCE END DATE: 11/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer